Company Filing History:
Years Active: 2016-2018
Title: Inventor Spotlight: Silke Köhr
Introduction:
Silke Köhr, a prolific inventor based in Teltow, Germany, has made significant contributions to the field of pharmaceuticals through his innovative patented inventions.
Latest Patents:
Köhr's latest patents include groundbreaking inventions in the realm of aryl-cyanoguanidine compounds. One of these patents involves protein-lysine N-methyltransferase SMYD2 inhibitors, specifically SMYD2-inhibitory substituted cyanoguanidine-pyrazolines. These compounds have shown promise in the prophylactic and therapeutic treatment of hyper-proliferative disorders, such as cancer and tumor disorders. Additionally, Köhr's other patent pertains to N-[4-(quinolin-4-yloxy)cyclohexyl(methyl)](hetero)arylcarboxamides, which have applications in treating and preventing various diseases, especially hyperproliferative diseases.
Career Highlights:
Silke Köhr is affiliated with Bayer Pharma Aktiengesellschaft, a prominent pharmaceutical company known for its innovative research and development efforts. Through his work at Bayer, Köhr has demonstrated expertise in the design and development of novel pharmaceutical compounds aimed at addressing critical health challenges.
Collaborations:
Köhr has collaborated closely with esteemed colleagues such as Jeffrey Stuart Mowat and Timo Stellfeld. These collaborations have led to the successful research and development of groundbreaking pharmaceutical inventions that have the potential to transform the treatment landscape for various diseases.
Conclusion:
In conclusion, Silke Köhr stands out as a leading inventor in the pharmaceutical industry, with a track record of pioneering patented inventions that hold great promise for improving healthcare outcomes. His dedication to innovation and collaboration underscores his commitment to advancing the field of pharmaceuticals and addressing unmet medical needs.